The burden of pneumococcal disease: The role of conjugate vaccines

Vaccine

Volumn 17, Issue 13-14, 1999, Pages 1674-1679

  Poland, Gregory A ^a  

^a Mayo Vaccine Research Group   (United States)

Author keywords

Pneumococcal vaccine; Protein conjugate

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACTIVE IMMUNIZATION; CONFERENCE PAPER; EUROPE; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; PREVALENCE; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; UNITED STATES; VACCINE PRODUCTION;

ADULT; BACTERIAL VACCINES; CLINICAL TRIALS; HUMANS; PNEUMOCOCCAL INFECTIONS; VACCINES, CONJUGATE;

EID: 0344267653     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00435-6     Document Type: Conference Paper

References (26)

1. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46:1-24.
2. Fedson DS, Musher DM. Pneumococcal vaccine. In: Plotkin SA, Mortimer Jr. EA, editors. Vaccines. 2nd ed. Philadelphia, PA: W.B. Saunders, 1994. p. 517-64.
3. Butler J.C., Hofmann J., Cetron M.S., Elliot J.A., Facklam R.R., Breiman R.F. The continued emergence of drug-resistant Streptococcus pneumoniae in the US: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J. Infect. Dis. 174:1996;986-993.
4. Avery O.T., Goebel W.F. Chemo-immunological studies on conjugated carbohydrates. II. Immunological specificity of synthetic sugar-proteins. J. Exp. Med. 50:1929;521-533.
5. Adams W.G., Deaver K.A., Cochi S.L., Plikaytis B.D., Zell E.R., Broome C.V., Wenger J.D. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 269:1993;221-226.
6. Robbins J.B., Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J. Infect. Dis. 161:1990;821-832.
7. Klein D.L. Pneumococcal conjugate vaccines: review and update. Microbial Drug Resistance. 1(1):1995;49-58.
8. Stein K.E. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 165:1992;S49-S52.
9. Steinhoff M.C., Edwards K., Keyserling H., Thoms M.L., Johnson C., Madore D., Hogeman D. A randomized comparison of three bivalent Streptococcus pneumoniae gylcoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr. Infect. Dis. 13(5):1994;368-372.
10. Butler J.C., Breiman R.F., Lipman H.B., Hofmann J., Facklam R.R. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the US, 1978-1994: implications for development of a conjugate vaccine. J. Infect. Dis. 171:1995;885-889.
11. Käyhty H., Eskola J. New vaccines for the prevention of pneumococcal infections. Emerg. Infect. Dis. 2:1996;289-298.
12. Dagan R., Melamed R., Muallem M., Piglansky L., Greenberg D., Abramson O., Mendelman P.M., Bohidar N., Yagupsky P. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J. Infect. Dis. 174:1996;1271-1278.
13. Käyhty H., Åhman H., Rönnberg P.-R., Tillikainen R., Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J. Infect. Dis. 172:1995;1273-1278.
14. Anderson E.L., Kennedy D.J., Geldmacher K.M., Donnelly J., Mendelman P.M. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J. Pediatr. 128(5 (Part 1)):1996;649-653.
15. Pichichero M., Shelly M.A., Treanor J.J. Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers. Pediatr. Infect. Dis. J. 16(1):1997;72-74.
16. Leach A., Ceesay S.J., Banya W.A.S., Greenwood B.M. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr. Infect. Dis. 15(4):1996;333-339.
17. King J.C. Jr., Vink P.E., Farley J.J., Parks M., Smilie M., Madore D., Lichenstein R., Malinoski F. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a liscensed polysaccharide vaccine in human immunodeficiency virus and nonhuman immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 15(3):1996;192-196.
18. Schneerson R., Robbins J.B., Parke J.C. Jr.et al. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect. Immun. 52(2):1986;519-528.
19. Anderson P., Betts R. Human adult immunogenicity of protein-coupled pneumococcal capsular antigens of serotypes prevalent in otitis media. Pediatr. Infect. Dis. J. 8(1):1989;S50-S53.
20. Fattom A., Lue C., Szu S.C., Mestecky J., Schiffman G., Bryla D., Vann W.F., Watson D., Kimzey L.M., Robbins J.B., Schneerson R. Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid. Infect. Immun. 58(7):1990;2309-2312.
21. Chan C.Y., Molrine D.C., George S., Tarbell N.J., Mauch P., Diller L., Shamberger R.C., Phillips N.R., Goorin A., Ambrosino D.M. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J. Infect. Dis. 173:1996;256-258.
22. Powers D.C., Anderson E.L., Lottenbach K., Mink C.M. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J. Infect. Dis. 173:1996;1014-1018.
23. Poland G.A., Jacobson R.M. The genetic basis for variation in antibody response to vaccines. Curr. Opin. Pediatr. 10:1998;208-215.
24. Poland G.A. Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response. Am. J. Hum. Genet. 62:1998;215-220.
25. Musher D.M., Groover J.E., Watson D.A., Pandey J.P., Rodriguez-Barradas M.C., Baughn R.E., Pollack M.S., Graviss E.A., de Andrade M., Amos C.I. Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. J. Invest. Med. 45:1997;57-68.
26. Nayak A.R., Tinge S.A., Tart R.C., McDaniel L.S., Briles D.E., Curtiss R.I. A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein a induces protective responses against Streptococcus pneumoniae. Infect. Immun. 66(8):1998;3744-3751.